FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914537553> ?p ?o ?g. }

• W2914537553 endingPage "629" @default.
• W2914537553 startingPage "619" @default.
• W2914537553 abstract "Melanoma is a highly immunogenic tumor and consequently, efforts have been centered on the development of immune-based treatments for this malignancy [1]. Interferons were initially described in the mid-1950s as proteins that interfere with viral replication [2, 3]. Interferons are cytokines that activate Janus kinases (Jak), which lead to phosphorylation and activation of transcription factors belonging to the signal transducer and activator of transcription (STAT) family [4, 5]. Interferon-alpha (IFN-α) became available for use in clinical trials in the mid-1980s [6]. Results suggested that IFN-α inhibited the proliferation of malignant cells and stimulated immune effectors; therefore, IFN-α was initially used in patients with advanced disease [7, 8]. Since then, several meta-analyses have demonstrated that high-dose adjuvant IFN-α (daily 20 MU/m2 intravenous induction therapy for 1 month followed by maintenance subcutaneous 10 MU/m2 three times per week for at least 1 year) can prolong the disease-free interval in high-risk melanoma patients [9].The introduction of checkpoint inhibitor therapy has revolutionized the adjuvant therapy of melanoma; however, there remains a role for IFN-α in this setting based on the potential for cancer immune escape or autoimmune events with CTLA-4 and PD-1 blocking antibodies [10–14]. There has also been significant advances in mitogen-activated protein kinase (MAPK) targeted therapies, particularly for BRAF (an intracellular signaling kinase) and MEK (signaling molecule downstream of BRAF). A recent clinical trial demonstrated significant improvement in both relapse-free survival and overall survival with adjuvant dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) in patients with stage III melanoma. These therapies are now approved for adjuvant therapy in BRAF mutated tumors [15]. However, since only approximately 40–50% of melanoma cells harbor an activating BRAF mutation, there still remains a role for IFN-α in this setting as the remaining 50–60% of melanomas would not be susceptible to BRAF-targeted therapies.IFN-α activates the Jak-STAT signaling pathway and induces synthesis of hundreds of different proteins [4, 5]. Our group has shown that STAT1-mediated gene regulation within immune effectors is necessary for mediating the anti-tumor effects of IFN-α and also that the amount IFN-α administered to melanoma patients is likely in excess of the optimal biological dose [4]. Indeed, high doses of IFN-α appear to be no more effective in the induction of phosphorylated STAT1 (p-STAT1) and in the transcription of interferon-stimulated genes (ISGs) than intermediate doses [16, 17]. Our group’s studies in genetically manipulated mice have shown that suppressors of cytokine signaling-1 (SOCS1) and SOCS3 negatively regulate IFN-induced Jak-STAT signal transduction, gene regulation and anti-melanoma activity, and that high doses of IFN-α can induce SOCS proteins [18, 19].We hypothesized that lower doses of IFN-α would be superior for induction of IFN signal transduction in patient immune cells. A prospective clinical trial was performed wherein patients eligible for adjuvant IFN-α-2b received 1 month of standard intravenous high-dose IFN-α-2b (20 MU/m2) followed by subcutaneous IFN-α-2b at a dose of 10 MU/m2 with dose reductions at set intervals down to a level of 4 MU/m2. Jak-STAT signal transduction and transcription of ISGs in patient peripheral blood mononuclear cells (PBMCs) were monitored during the course of adjuvant IFN-α therapy. The objective of this pilot study was to determine if lower doses of IFN-α were as effective in the induction of IFN signal transduction and gene expression as the standard high dose regimen." @default.
• W2914537553 created "2019-02-21" @default.
• W2914537553 creator A5007148032 @default.
• W2914537553 creator A5009792840 @default.
• W2914537553 creator A5016389095 @default.
• W2914537553 creator A5044766130 @default.
• W2914537553 creator A5045110376 @default.
• W2914537553 creator A5049236526 @default.
• W2914537553 creator A5054983553 @default.
• W2914537553 creator A5060897770 @default.
• W2914537553 creator A5061388555 @default.
• W2914537553 creator A5063621818 @default.
• W2914537553 creator A5081220636 @default.
• W2914537553 creator A5084303946 @default.
• W2914537553 date "2019-02-06" @default.
• W2914537553 modified "2023-10-15" @default.
• W2914537553 title "A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma" @default.
• W2914537553 cites W1501257267 @default.
• W2914537553 cites W1502556912 @default.
• W2914537553 cites W1510351486 @default.
• W2914537553 cites W1582258347 @default.
• W2914537553 cites W1828940258 @default.
• W2914537553 cites W1908752382 @default.
• W2914537553 cites W1911828475 @default.
• W2914537553 cites W1977225082 @default.
• W2914537553 cites W2008578655 @default.
• W2914537553 cites W2023145844 @default.
• W2914537553 cites W2040717595 @default.
• W2914537553 cites W2044389879 @default.
• W2914537553 cites W2060736581 @default.
• W2914537553 cites W2060897674 @default.
• W2914537553 cites W2060926084 @default.
• W2914537553 cites W2097747927 @default.
• W2914537553 cites W2099289479 @default.
• W2914537553 cites W2110076708 @default.
• W2914537553 cites W2112121482 @default.
• W2914537553 cites W2118449798 @default.
• W2914537553 cites W2123628301 @default.
• W2914537553 cites W2129814407 @default.
• W2914537553 cites W2131772284 @default.
• W2914537553 cites W2136179839 @default.
• W2914537553 cites W2137978694 @default.
• W2914537553 cites W2147090478 @default.
• W2914537553 cites W2152980179 @default.
• W2914537553 cites W2166662937 @default.
• W2914537553 cites W2172292246 @default.
• W2914537553 cites W2265287921 @default.
• W2914537553 cites W2269457085 @default.
• W2914537553 cites W2324567936 @default.
• W2914537553 cites W2399883887 @default.
• W2914537553 cites W2572174216 @default.
• W2914537553 cites W2752210999 @default.
• W2914537553 cites W3027540567 @default.
• W2914537553 doi "https://doi.org/10.1007/s00262-019-02308-w" @default.
• W2914537553 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6447692" @default.
• W2914537553 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30725205" @default.
• W2914537553 hasPublicationYear "2019" @default.
• W2914537553 type Work @default.
• W2914537553 sameAs 2914537553 @default.
• W2914537553 citedByCount "6" @default.
• W2914537553 countsByYear W29145375532020 @default.
• W2914537553 countsByYear W29145375532021 @default.
• W2914537553 countsByYear W29145375532022 @default.
• W2914537553 countsByYear W29145375532023 @default.
• W2914537553 crossrefType "journal-article" @default.
• W2914537553 hasAuthorship W2914537553A5007148032 @default.
• W2914537553 hasAuthorship W2914537553A5009792840 @default.
• W2914537553 hasAuthorship W2914537553A5016389095 @default.
• W2914537553 hasAuthorship W2914537553A5044766130 @default.
• W2914537553 hasAuthorship W2914537553A5045110376 @default.
• W2914537553 hasAuthorship W2914537553A5049236526 @default.
• W2914537553 hasAuthorship W2914537553A5054983553 @default.
• W2914537553 hasAuthorship W2914537553A5060897770 @default.
• W2914537553 hasAuthorship W2914537553A5061388555 @default.
• W2914537553 hasAuthorship W2914537553A5063621818 @default.
• W2914537553 hasAuthorship W2914537553A5081220636 @default.
• W2914537553 hasAuthorship W2914537553A5084303946 @default.
• W2914537553 hasBestOaLocation W29145375531 @default.
• W2914537553 hasConcept C111335779 @default.
• W2914537553 hasConcept C121608353 @default.
• W2914537553 hasConcept C126322002 @default.
• W2914537553 hasConcept C141071460 @default.
• W2914537553 hasConcept C143998085 @default.
• W2914537553 hasConcept C203014093 @default.
• W2914537553 hasConcept C2524010 @default.
• W2914537553 hasConcept C2775944032 @default.
• W2914537553 hasConcept C2776178377 @default.
• W2914537553 hasConcept C2777658100 @default.
• W2914537553 hasConcept C2777863537 @default.
• W2914537553 hasConcept C2777982462 @default.
• W2914537553 hasConcept C2909179924 @default.
• W2914537553 hasConcept C33923547 @default.
• W2914537553 hasConcept C49453240 @default.
• W2914537553 hasConcept C502942594 @default.
• W2914537553 hasConcept C64943373 @default.
• W2914537553 hasConcept C71924100 @default.
• W2914537553 hasConceptScore W2914537553C111335779 @default.
• W2914537553 hasConceptScore W2914537553C121608353 @default.

• next